Multiple Sclerosis
Conference Coverage
Ozanimod shows long-term safety, despite a pandemic
Open-label study confirms efficacy and COVID-19–related safety.
Conference Coverage
B-cell therapy for MS may impact COVID-19 vaccination
A prospective study found improved neutralizing antibody response with more time elapsed since therapy and vaccination.
Conference Coverage
Evidence mounts for paramagnetic rim lesions in diagnosing MS
The presence and number of iron rim lesions hold a prognostic value for long-term disability in MS.
Conference Coverage
Spinal cord atrophy predicts ‘silent progression’ in MS
This is a potentially important biomarker for disease progression that may otherwise go unrecognized by clinicians and patients.
Conference Coverage
B-cell repletion is common with MS drug, but no symptom worsening
While “surprising,” these findings do not prove that B-cell repletion does not put someone at risk.
Conference Coverage
Brief, automated cognitive test may offer key advantages in MS
The automated NIH Toolbox Cognition Battery may be used as an alternative to other gold-standard measures which may cover limited domains or...
Conference Coverage
Specialty pharmacists may speed time to MS treatment
Because there currently is no established DMT selection algorithm, specialty pharmacists can assist in medication education and management.
Conference Coverage
Cannabis use common for MS-related spasticity
The new data reflect the latest patterns of use amid sweeping changes in recreational and medical marijuana laws.
Conference Coverage
New consensus guideline on clinical MRI use in MS
The updated protocol is beneficial in providing “simple, reasonable guidelines that can be easily acquired at almost any imaging location in the U...
Conference Coverage
Multiple DMTs linked to alopecia, especially in women
Several medications weren’t previously implicated in hair loss, researchers report.